Mengis Capital Management’s Boston Scientific BSX Stock Holding History

Mengis Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.95M	Buy	+47,066	New	+$3.77M	0.51%	54

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mengis Capital Management's BSX Position: Q1 2026 in Review

Mengis Capital Management opened a new position in Boston Scientific (BSX) in Q1 2026: 47,066 shares worth $2.95M. The stake represents 0.51% of the portfolio and ranks #54 among its holdings.

1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Mengis Capital Management held 47,066 shares of Boston Scientific worth $2.95M as of Q1 2026.
Boston Scientific was a new Mengis Capital Management position in Q1 2026.
Boston Scientific made up 0.51% of Mengis Capital Management's portfolio in Q1 2026, its #54 holding.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Mengis Capital Management's 13F filing for Q1 2026, filed 12 May 2026.